Zepbound Philippines 2026

Eli Lilly sells tirzepatide under two brand names. Mounjaro is the version marketed for type 2 diabetes. Zepbound is the version marketed for obesity. Different box, different indication on the label, different pricing strategy in the markets where both exist. Identical active molecule, identical dual-receptor mechanism hitting GLP-1 and GIP, identical dose ladder in milligrams.

This matters more here than it does in a market where both brands sit on the same shelf. In the Philippines the branded conversation is a Mounjaro conversation, and a buyer who has anchored on the word Zepbound tends to make one of two mistakes. The first is assuming the drug is unavailable because the brand is, and paying for an international shipment they did not need. The second is worse: treating a listing that says Zepbound as proof of a superior or more recent product, which is exactly the hook a counterfeit seller wants you to bite on.

The practical rule is to shop by molecule. Ask for tirzepatide, ask what brand and dose the pharmacy actually has, and compare the price per milligram rather than per box. Anyone quoting a premium for the Zepbound label over the Mounjaro label is charging you for packaging. The same logic applies one molecule over: Ozempic and Wegovy are both semaglutide, which I cover in the Wegovy versus Ozempic filing.

Start with the honest boundary. No Philippine registration has been identified for the Zepbound brand. Searches that turn up Zepbound regulatory paperwork return United States documents, not Philippine ones, so this page carries no PH peso price for a Zepbound box and you should treat any listing that quotes one as a claim about an import rather than a local product.

The molecule itself is another matter, and this is where the page has changed. Tirzepatide under the Mounjaro brand is now plainly listed by the chains: Watsons carried all six KwikPen strengths when checked in August 2026, and Rose Pharmacy listed the 5mg pen at ₱13,600, out of stock at the time. What the listings show is a rationing pattern rather than an absence, since every Watsons Mounjaro strength was click and collect rather than delivery. Stock is intermittent everywhere in the class, and constrained allocations land in Metro Manila first and reach provincial branches later and thinner. If you are outside the metro, read the courier-served reality in my Davao filing before you plan around a local pharmacy trip.

What does not work is the marketplace. Lazada, Shopee, and Facebook reseller listings are the documented counterfeit channel for GLP-1 pens in this country, and the brand-confusion problem makes them more dangerous, not less: a seller who knows buyers are searching for a name the local market does not carry has a ready-made story for why their supply is special. Treat every one of those listings as unverifiable. The counterfeit pen filing covers what the fakes look like.

Research-grade tirzepatide ships as lyophilized powder in a vial rather than as a pre-filled pen. You reconstitute it with bacteriostatic water, draw the dose with an insulin syringe, and do your own arithmetic. That format is why it survives a Philippine courier network: freeze-dried powder tolerates transit heat in a way that a reconstituted solution does not, which is what makes a nationwide market possible at all.

The trade-offs run in both directions and anyone who tells you otherwise is selling something. Research-grade is not automatically inferior and it is not automatically equivalent. The supplier is the whole variable. My non-negotiables have not changed: a third-party certificate of analysis for the specific batch, insulated cold-chain packaging, clear reconstitution guidance, and a price that sits inside the market range rather than half of it. A quote at half the going rate means underdosed or counterfeit far more often than it means a bargain. The COA reference covers how to read the document you are being handed.

The other half of the diligence shifts to you as well. Baseline labs before starting, periodic panels during, and honest self-assessment on tolerability. Private lab work in this country is cheap and available everywhere, which removes the usual excuse for skipping it.

Zepbound exists as a separate brand because tirzepatide was studied specifically in an obesity population. SURMOUNT-1, published in 2022, reported roughly 22.5% average body weight reduction over 72 weeks. For comparison, STEP 1 reported about 14.9% for semaglutide 2.4mg in 2021, and SURMOUNT-5 compared the two molecules head to head with tirzepatide ahead.

Two caveats I repeat on every one of these filings. First, trial averages describe populations under supervised protocols with dietary and lifestyle components, not individuals running a self-directed protocol from a vial. Second, the dual-receptor mechanism that produces the larger average also changes the side-effect picture rather than eliminating it. The class-wide adverse-event material is in my GLP-1 side effects filing, and none of it is medical advice.

What this section used to say. It carried a personal receipt: a named pharmacy, a specific peso figure paid on a specific day, and a hospital premium calculated from it. That receipt is gone rather than adjusted. The counters it named publish no prices, so no reader could ever check it, and the figure it quoted was far above what the chains actually list.

What the stockout pattern actually looks like. The constraint on tirzepatide here is availability, not the absence of a published price. Every Mounjaro strength checked at Watsons was click and collect rather than delivery, and Rose Pharmacy listed the 5mg KwikPen as out of stock. Switching molecule or channel because a shelf was empty is a different decision from switching because a prescriber recommended it, and only one of those belongs in a treatment plan.

The arithmetic, corrected. A Mounjaro 5mg KwikPen at ₱13,550 is about $242 a month, roughly $60 a weekly dose, and about $2,904 a year. At 10mg the pen is ₱22,950, about $410 a month and $4,918 a year. Research-grade tirzepatide at 10mg weekly runs about $1,150 a year, plus roughly $380 a year for quarterly private lab panels, so about $1,530 all-in. The gap is real, and it is a gap against a prescription medicine dispensed by a registered pharmacy.

On the brand name itself. I have never once been offered a Zepbound box in this country, and I have asked. Every Filipino-market conversation about this molecule is a Mounjaro conversation or a vial conversation. If someone shows you a Zepbound listing here, the interesting question is not the price. It is where they say they got it.